Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Worldwide Offices
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031, Garnering 15.1% CAGR: TMR Report

      This image opens in the lightbox

      News provided by

      Transparency Market Research

      30 Oct, 2023, 15:30 GMT

      Share this article

      Share this article


      Research and development advances and supportive regulatory environments contribute to muscle wasting disorder demand

      WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- The muscle wasting disorders market generated revenues worth US$ 12.7 billion in 2022. The market is predicted to reach US$ 45.4 billion in 2031. Between 2023 and 2031, the market is expected to register a growth rate of 15.1%.

      Many diseases and conditions cause muscle wasting and weakness, like aging, cancer, sepsis, cachexia, denervation, inactivity, HIV-acquired immunity syndrome (AIDS), burns, chronic kidney or heart failure, unloading/microgravity, and muscular dystrophies.

      Various illnesses and diseases can cause muscle wasting. A study conducted by Trusted Source in 2017 concluded that cancer, heart failure, and sepsis have a worse prognosis when muscle wasting is present. Muscle wasting refers to the gradual loss of muscle tissue. In addition to ALS, muscular dystrophy, and MS, it can also be caused by other medical conditions.

      Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39452

      Muscle Wasting Disorders Market Report Scope:

      Report Coverage

      Details 

      Forecast Period 

      2023-2031

      Base Year 

      2017-2021

      Size in 2022

      US$ 12.7 Bn

      Forecast (Value) in 2031

      More than US$ 45.4 Bn

      Growth Rate (CAGR)

      15.1 %

      No. of Pages

      186 Pages

      Segments covered

      Type, Treatment Type, End-user

      Key Findings of the Market Report

      • The use of pharmaceutical interventions represents yet another potential pathway for progress.
      • Based on treatment type, medication type is expected to lead the market.
      • Among the end-user segments, the hospital segment is expected to increase demand for muscle wasting disorder.
      • Between 2023 and 2031, North America is expected to dominate sales.
      • Physiological atrophy is expected to dominate the market for muscle wasting disorders.

      Market Trends for Muscle Wasting Disorders

      • Regulatory agencies are increasingly recognizing muscle wasting disorders, and promising therapies are receiving incentives and fast-track designations. The investment in this area is therefore encouraged by pharmaceutical companies.
      • In recent years, many individuals worldwide have been affected by muscle-wasting disorders, including muscular dystrophy and amyotrophic lateral sclerosis (ALS). As the population ages and awareness rises, this trend will likely continue.
      • New treatment options and therapies are being developed to treat muscle wasting disorders. Several advanced approaches are being explored, including gene therapy, stem cell therapy, and others. Various therapeutic approaches are proposed to slow or even reverse the progression of these disorders.
      • Muscle wasting disorders are becoming more common as new treatments are approved. A physical therapist and pharmaceuticals or medical devices may be used as a treatment.
      • Pharmaceutical companies actively developed drugs and biologics for the treatment of muscle wasting. Some companies that work on muscle atrophy pathways are researching small molecules and biologics.
      • Researchers are discovering new therapeutic targets and potential treatments for muscle atrophy based on molecular and genetic mechanisms. As a result, innovative therapies and pharmaceuticals are encouraged to be developed.

      Global Market for Muscle Wasting Disorders Regional Outlook

      • Advanced diagnostics and a high awareness of muscle atrophy in North America are the primary reasons for the market's success. Various governments, including those in the United States, a major regional market, are initiating campaigns to treat patients.
      • As geriatric populations increase, researchers and developers at pharmaceutical companies are increasing their development programs. Chronic diseases are also on the rise. As a result of these factors, the muscle wasting disorder market is growing.
      • Asia Pacific has the largest population and is projected to grow faster due to improved healthcare infrastructure. Increased government funding for research, increased cancer awareness in developing countries, and patient support programs are expected to boost the muscle wasting disorders market in the future.

      Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=39452

      Global Muscle Wasting Disorders: Key Players

      A number of players compete for a limited share of the global muscle-wasting disorders market. An analysis of the global muscle-wasting disorders market has been provided in the report, which includes information such as company overviews, financial profiles, business strategies, product portfolios, and business segments. Key market players in the muscle wasting disorders landscape include:

      • Biogen, Inc.
      • F. Hoffmann-La Roche Ltd
      • Novartis AG
      • Ionis Pharmaceuticals, Inc.
      • Sarepta Therapeutics, Inc.
      • Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
      • PTC Therapeutics, Inc.
      • Teva Pharmaceutical Industries Ltd.

      Key Developments in the Global Muscle Wasting Disorders Market

      • In June 2023, the U.S. Food and Drug Administration approved Elevidys, a gene therapy for treating children with Duchenne muscular dystrophy (DMD) who are between 4 and 5 years old with a confirmed mutation in the DMD gene and are not unable to undergo treatment due to a pre-existing medical condition.
      • In August 2023, the European Commission extended Evrysdi's EU marketing authorization to include infants born between birth and the age of two months who have one to four copies of the SMN2 gene.

      Global Muscle Wasting Disorders Market: Segmentation

      • Type
        • Muscular Dystrophy
          • Duchenne Muscular Dystrophy (DMD)
          • Becker Muscular Dystrophy (BMD)
          • Myotonic Muscular Dystrophy
          • Congenital Muscular Dystrophy
          • Limb-Girdle Muscular Dystrophy
          • Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
        • Muscular Atrophy
          • Physiologic Atrophy
          • Pathologic Atrophy
          • Neurogenic Atrophy
      • Treatment Type
        • Medications
        • Physical Therapy
          • Ultrasound Therapy
          • Electric Simulation
        • Nutritional Therapy
        • Surgery
        • Gene Therapy
        • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)
      • End-user
        • Hospitals
        • Rehab Centers
        • Specialty Clinics
        • Others (Homecare, etc.)
      • Region
        • North America
        • Latin America
        • Europe
        • Asia Pacific
        • Middle East & Africa

      Place an Order Copy of Muscle Wasting Disorders Market Report at:  https://www.transparencymarketresearch.com/checkout.php?rep_id=39452&ltype=S

      More Trending Report by Transparency Market Research:

      Allogeneic Stem Cell Market - The global industry was valued at US$ 941.8 Mn in 2022; It is projected to grow at a CAGR of 6.3% from 2023 to 2031 and reach more than US$ 1.6 Bn by the end of 2031

      Liposome Drug Delivery Market - The global industry was valued at US$ 4.7 Bn in 2022; It is projected to grow at a CAGR of 8.5% from 2023 to 2031 and reach more than US$ 10.0 Bn by the end of 2031

      Empty Capsules Market - The global industry was valued at US$ 2.9 Bn in 2022; It is projected to grow at a CAGR of 7.7% from 2023 to 2031 and reach more than US$ 5.6 Bn by the end of 2031

      About Transparency Market Research

      Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

      Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

      Contact:

      Nikhil Sawlani
      Transparency Market Research Inc.
      CORPORATE HEADQUARTER DOWNTOWN,
      1000 N. West Street,
      Suite 1200, Wilmington, Delaware 19801 USA
      Tel: +1-518-618-1030
      USA – Canada Toll Free: 866-552-3453
      Website: https://www.transparencymarketresearch.com   
      Blog: https://tmrblog.com   
      Email: sales@transparencymarketresearch.com

      Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.